{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:27:56Z","timestamp":1773714476270,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"DOI":"10.1007\/s10689-025-00490-8","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:21:04Z","timestamp":1758097264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer spectrum in Mexican patients with the CHEK2 p.(Leu236Pro) variant: a retrospective study"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-3888","authenticated-orcid":false,"given":"L. Leonardo","family":"Flores-Lagunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5458-7201","authenticated-orcid":false,"given":"Rosa Mar\u00eda","family":"Alvarez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-7938","authenticated-orcid":false,"given":"Carolina","family":"Molina-Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-8415","authenticated-orcid":false,"given":"Marco","family":"Jimenez-Olivares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9107-6549","authenticated-orcid":false,"given":"Pablo Arturo","family":"Acosta-Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7925-6661","authenticated-orcid":false,"given":"Joaquin","family":"Garc\u00eda-Solorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2924-2621","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Prida-Riba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0079-8476","authenticated-orcid":false,"given":"Karol","family":"Carillo-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6224-6829","authenticated-orcid":false,"given":"Elvia Cristina","family":"Mendoza-Caamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2350-7045","authenticated-orcid":false,"given":"Marcela Ang\u00e9lica","family":"De la Fuente-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-197X","authenticated-orcid":false,"given":"Ver\u00f3nica Zoraya","family":"Fragoso-Ontiveros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-581X","authenticated-orcid":false,"given":"Rodrigo Estefano","family":"Reyes Casarrubias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-8505","authenticated-orcid":false,"given":"Carmen","family":"Alaez-Verson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"490_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, G\u00f3rski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131\u20131135. https:\/\/doi.org\/10.1086\/426403","journal-title":"Am J Hum Genet"},{"key":"490_CR2","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.gim.2023.100870","volume":"25","author":"H Hanson","year":"2023","unstructured":"Hanson H, Astiazaran-Symonds E, Amendola LM et al (2023) Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American college of medical genetics and genomics (ACMG). Genet Med Off J Am Coll Med Genet 25:100870. https:\/\/doi.org\/10.1016\/j.gim.2023.100870","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"490_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Breast Cancer Association Consortium, Dorling L, Carvalho S et al (2021) Breast cancer risk Genes - Association analysis in more than 113,000 women. N Engl J Med 384:428\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1913948","journal-title":"N Engl J Med"},{"key":"490_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","volume":"34","author":"N Tung","year":"2016","unstructured":"Tung N, Lin NU, Kidd J et al (2016) Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 34:1460\u20131468. https:\/\/doi.org\/10.1200\/JCO.2015.65.0747","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"490_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1086\/341943","volume":"71","author":"P Vahteristo","year":"2002","unstructured":"Vahteristo P, Bartkova J, Eerola H et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of Familial breast cancer. Am J Hum Genet 71:432\u2013438. https:\/\/doi.org\/10.1086\/341943","journal-title":"Am J Hum Genet"},{"key":"490_CR6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/ijc.32385","volume":"145","author":"P Kleiblova","year":"2019","unstructured":"Kleiblova P, Stolarova L, Krizova K et al (2019) Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer 145:1782\u20131797. https:\/\/doi.org\/10.1002\/ijc.32385","journal-title":"Int J Cancer"},{"key":"490_CR7","doi-asserted-by":"publisher","first-page":"e0140819","DOI":"10.1371\/journal.pone.0140819","volume":"10","author":"O Havranek","year":"2015","unstructured":"Havranek O, Kleiblova P, Hojny J et al (2015) Association of germline CHEK2 gene variants with risk and prognosis of Non-Hodgkin lymphoma. PLoS ONE 10:e0140819. https:\/\/doi.org\/10.1371\/journal.pone.0140819","journal-title":"PLoS ONE"},{"key":"490_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ijc.29426","volume":"137","author":"M Sio\u0142ek","year":"2015","unstructured":"Sio\u0142ek M, Cybulski C, G\u0105sior-Perczak D et al (2015) CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer 137:548\u2013552. https:\/\/doi.org\/10.1002\/ijc.29426","journal-title":"Int J Cancer"},{"key":"490_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamaoncol.2019.0022","volume":"5","author":"E Zlowocka-Perlowska","year":"2019","unstructured":"Zlowocka-Perlowska E, Narod SA, Cybulski C (2019) CHEK2 alleles predispose to renal cancer in Poland. JAMA Oncol 5:576. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0022","journal-title":"JAMA Oncol"},{"key":"490_CR10","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41436-021-01234-6","volume":"23","author":"ER Woodward","year":"2021","unstructured":"Woodward ER, van Veen EM, Forde C et al (2021) Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. Genet Med Off J Am Coll Med Genet 23:1969\u20131976. https:\/\/doi.org\/10.1038\/s41436-021-01234-6","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"490_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/cancers10100361","volume":"10","author":"R Quezada Urban","year":"2018","unstructured":"Quezada Urban R, D\u00edaz Vel\u00e1squez CE, Gitler R et al (2018) Comprehensive analysis of germline variants in Mexican patients with hereditary breast and ovarian cancer susceptibility. Cancers 10:361. https:\/\/doi.org\/10.3390\/cancers10100361","journal-title":"Cancers"},{"key":"490_CR12","unstructured":"Flores Lagunes LL, Al\u00e1ez Vers\u00f3n C (2019) Prevalencia de mutaciones germinales en genes de susceptibilidad de c\u00e1ncer en pacientes con c\u00e1ncer de mama y\/o ovario y riesgo gen\u00e9tico. Tesis de Maestr\u00eda, Universidad Nacional Aut\u00f3noma de M\u00e9xico"},{"key":"490_CR13","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/cncr.32083","volume":"125","author":"JN Weitzel","year":"2019","unstructured":"Weitzel JN, Neuhausen SL, Adamson A et al (2019) Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer 125:2829\u20132836. https:\/\/doi.org\/10.1002\/cncr.32083","journal-title":"Cancer"},{"key":"490_CR14","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G et al (2015) Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336\u20132346. https:\/\/doi.org\/10.1056\/NEJMoa1508054","journal-title":"N Engl J Med"},{"key":"490_CR15","doi-asserted-by":"publisher","first-page":"e2339571","DOI":"10.1001\/jamanetworkopen.2023.39571","volume":"6","author":"E Chen","year":"2023","unstructured":"Chen E, Facio FM, Aradhya KW et al (2023) Rates and classification of variants of uncertain significance in hereditary disease genetic testing. JAMA Netw Open 6:e2339571. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39571","journal-title":"JAMA Netw Open"},{"key":"490_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/humu.23728","volume":"40","author":"A Delimitsou","year":"2019","unstructured":"Delimitsou A, Fostira F, Kalfakakou D et al (2019) Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system. Hum Mutat 40:631\u2013648. https:\/\/doi.org\/10.1002\/humu.23728","journal-title":"Hum Mutat"},{"key":"490_CR17","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-23-0212","volume":"29","author":"L Stolarova","year":"2023","unstructured":"Stolarova L, Kleiblova P, Zemankova P et al (2023) ENIGMA CHEK2gether project: a comprehensive study identifies functionally impaired CHEK2 germline missense variants associated with increased breast cancer risk. Clin Cancer Res Off J Am Assoc Cancer Res 29:3037\u20133050. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0212","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"490_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","volume":"8","author":"BL Bychkovsky","year":"2022","unstructured":"Bychkovsky BL, Agaoglu NB, Horton C et al (2022) Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical Care-Checking CHEK2. JAMA Oncol 8:1598\u20131606. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4071","journal-title":"JAMA Oncol"},{"key":"490_CR19","doi-asserted-by":"publisher","first-page":"e2451361","DOI":"10.1001\/jamanetworkopen.2024.51361","volume":"8","author":"BL Bychkovsky","year":"2025","unstructured":"Bychkovsky BL, Agaoglu NB, Horton C et al (2025) Double CHEK2 pathogenic and Low-Risk variants and associated cancer phenotypes. JAMA Netw Open 8:e2451361. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.51361","journal-title":"JAMA Netw Open"},{"key":"490_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17:405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"490_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41586-023-06595-3","volume":"622","author":"A Ziyatdinov","year":"2023","unstructured":"Ziyatdinov A, Torres J, Alegre-D\u00edaz J et al (2023) Genotyping, sequencing and analysis of 140,000 adults from Mexico City. Nature 622:784\u2013793. https:\/\/doi.org\/10.1038\/s41586-023-06595-3","journal-title":"Nature"},{"key":"490_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN et al (2023) NCCN Guidelines\u00ae insights: genetic\/familial High-Risk assessment: breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Cancer Netw JNCCN 21:1000\u20131010. https:\/\/doi.org\/10.6004\/jnccn.2023.0051","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"490_CR23","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","volume":"33","author":"ME Robson","year":"2015","unstructured":"Robson ME, Bradbury AR, Arun B et al (2015) American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol Off J Am Soc Clin Oncol 33:3660\u20133667. https:\/\/doi.org\/10.1200\/JCO.2015.63.0996","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"490_CR24","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.30498","volume":"123","author":"SS Buys","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A et al (2017) A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 123:1721\u20131730. https:\/\/doi.org\/10.1002\/cncr.30498","journal-title":"Cancer"},{"key":"490_CR25","doi-asserted-by":"publisher","unstructured":"Campos FAB, Rouleau E, Torrezan GT et al (2021) Genetic landscape of male breast cancer. https:\/\/doi.org\/10.3390\/cancers13143535. Cancers 13:","DOI":"10.3390\/cancers13143535"},{"key":"490_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.canlet.2004.07.002","volume":"215","author":"N Sodha","year":"2004","unstructured":"Sodha N, Wilson C, Bullock SL et al (2004) Analysis of Familial male breast cancer for germline mutations in CHEK2. Cancer Lett 215:187\u2013189. https:\/\/doi.org\/10.1016\/j.canlet.2004.07.002","journal-title":"Cancer Lett"},{"key":"490_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","volume":"161","author":"M Pritzlaff","year":"2017","unstructured":"Pritzlaff M, Summerour P, McFarland R et al (2017) Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat 161:575\u2013586. https:\/\/doi.org\/10.1007\/s10549-016-4085-4","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12885-017-3631-8","volume":"17","author":"S Hallamies","year":"2017","unstructured":"Hallamies S, Pelttari LM, Poikonen-Saksela P et al (2017) CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer 17:620. https:\/\/doi.org\/10.1186\/s12885-017-3631-8","journal-title":"BMC Cancer"},{"key":"490_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40291-018-0344-x","volume":"22","author":"M Liang","year":"2018","unstructured":"Liang M, Zhang Y, Sun C et al (2018) Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther 22:397\u2013407. https:\/\/doi.org\/10.1007\/s40291-018-0344-x","journal-title":"Mol Diagn Ther"},{"key":"490_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/jmg-2023-109826","volume":"61","author":"DG Evans","year":"2024","unstructured":"Evans DG, Burghel GJ, Howell SJ et al (2024) Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2. J Med Genet 61:853\u2013855. https:\/\/doi.org\/10.1136\/jmg-2023-109826","journal-title":"J Med Genet"},{"key":"490_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-007-9689-2","volume":"110","author":"M Falchetti","year":"2008","unstructured":"Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1\/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110:161\u2013167. https:\/\/doi.org\/10.1007\/s10549-007-9689-2","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-018-4661-x","volume":"169","author":"F Fostira","year":"2018","unstructured":"Fostira F, Saloustros E, Apostolou P et al (2018) Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Res Treat 169:105\u2013113. https:\/\/doi.org\/10.1007\/s10549-018-4661-x","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10549-019-05429-z","volume":"178","author":"R Scarpitta","year":"2019","unstructured":"Scarpitta R, Zanna I, Aretini P et al (2019) Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Breast Cancer Res Treat 178:557\u2013564. https:\/\/doi.org\/10.1007\/s10549-019-05429-z","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ijc.11384","volume":"108","author":"K Syrj\u00e4koski","year":"2004","unstructured":"Syrj\u00e4koski K, Kuukasj\u00e4rvi T, Auvinen A, Kallioniemi O-P (2004) CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 108:475\u2013476. https:\/\/doi.org\/10.1002\/ijc.11384","journal-title":"Int J Cancer"},{"key":"490_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1186\/s12885-021-08718-3","volume":"21","author":"M Szwiec","year":"2021","unstructured":"Szwiec M, Tomiczek-Szwiec J, Klu\u017aniak W et al (2021) Genetic predisposition to male breast cancer in Poland. BMC Cancer 21:975. https:\/\/doi.org\/10.1186\/s12885-021-08718-3","journal-title":"BMC Cancer"},{"key":"490_CR36","doi-asserted-by":"publisher","unstructured":"Tedaldi G, Tebaldi M, Zampiga V et al (2020) Male breast cancer: results of the application of multigene panel testing to an Italian cohort of patients. Diagn Basel Switz 10. https:\/\/doi.org\/10.3390\/diagnostics10050269","DOI":"10.3390\/diagnostics10050269"},{"key":"490_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ejhg.2013.85","volume":"22","author":"PEA Huijts","year":"2014","unstructured":"Huijts PEA, Hollestelle A, Balliu B et al (2014) CHEK2*1100delC homozygosity in the Netherlands\u2013prevalence and risk of breast and lung cancer. Eur J Hum Genet EJHG 22:46\u201351. https:\/\/doi.org\/10.1038\/ejhg.2013.85","journal-title":"Eur J Hum Genet EJHG"},{"key":"490_CR38","doi-asserted-by":"publisher","first-page":"101101","DOI":"10.1016\/j.gim.2024.101101","volume":"26","author":"S Hini\u0107","year":"2024","unstructured":"Hini\u0107 S, Cybulski C, Van der Post RS et al (2024) The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet Med Off J Am Coll Med Genet 26:101101. https:\/\/doi.org\/10.1016\/j.gim.2024.101101","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"490_CR39","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41431-022-01270-z","volume":"31","author":"I Bottillo","year":"2023","unstructured":"Bottillo I, Savino E, Majore S et al (2023) Two unrelated cases with biallelic CHEK2 variants:a novel condition with constitutional chromosomal instability? Eur J Hum Genet EJHG 31:474\u2013478. https:\/\/doi.org\/10.1038\/s41431-022-01270-z","journal-title":"Eur J Hum Genet EJHG"},{"key":"490_CR40","doi-asserted-by":"publisher","unstructured":"Hodan R, Gupta S, Weiss JM Genetic\/Familial High-Risk Assessment: Colorectal, Endometrial, and, Gastric et al (2024) Version 3.2024, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Cancer Netw JNCCN 22:695\u2013711. https:\/\/doi.org\/10.6004\/jnccn.2024.0061","DOI":"10.6004\/jnccn.2024.0061"},{"key":"490_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","volume":"147","author":"J Lilyquist","year":"2017","unstructured":"Lilyquist J, LaDuca H, Polley E et al (2017) Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol 147:375\u2013380. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.030","journal-title":"Gynecol Oncol"},{"key":"490_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","volume":"5","author":"H-M Lu","year":"2019","unstructured":"Lu H-M, Li S, Black MH et al (2019) Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing. JAMA Oncol 5:51\u201357. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2956","journal-title":"JAMA Oncol"},{"key":"490_CR43","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1200\/JCO.2021.39.15_suppl.5084","volume":"39","author":"E Nizialek","year":"2021","unstructured":"Nizialek E, Lotan TL, Isaacs WB et al (2021) The somatic mutation landscape of germline CHEK2-altered prostate cancer. J Clin Oncol 39:5084\u20135084. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5084","journal-title":"J Clin Oncol"},{"key":"490_CR44","doi-asserted-by":"publisher","first-page":"e2300628","DOI":"10.1200\/PO.23.00628","volume":"8","author":"R Manneh","year":"2024","unstructured":"Manneh R, Verson CA, Martin A et al (2024) Prospective study of homologous recombination repair gene mutation prevalence in patients with advanced prostate cancer from Latin america: challenges and future approaches. JCO Precis Oncol 8:e2300628. https:\/\/doi.org\/10.1200\/PO.23.00628","journal-title":"JCO Precis Oncol"},{"key":"490_CR45","first-page":"15708","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Dai B, Ye D (2015) CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8:15708\u201315715","journal-title":"Int J Clin Exp Med"},{"key":"490_CR46","doi-asserted-by":"publisher","unstructured":"Brand\u00e3o A, Paulo P, Maia S et al (2020) The CHEK2 variant C.349A\u2009>\u2009G is associated with prostate cancer risk and carriers share a common ancestor. Cancers. https:\/\/doi.org\/10.3390\/cancers12113254","DOI":"10.3390\/cancers12113254"},{"key":"490_CR47","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ygyno.2022.04.003","volume":"165","author":"HC Karpel","year":"2022","unstructured":"Karpel HC, Chern J-Y, Smith JM et al (2022) Utility of germline multi-gene panel testing in patients with endometrial cancer. Gynecol Oncol 165:546\u2013551. https:\/\/doi.org\/10.1016\/j.ygyno.2022.04.003","journal-title":"Gynecol Oncol"},{"key":"490_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/dna.2008.0781","volume":"28","author":"DV Konstantinova","year":"2009","unstructured":"Konstantinova DV, Kadiyska TK, Kaneva RP et al (2009) CHEK2 I157T and endometrial cancer. DNA Cell Biol 28:9\u201312. https:\/\/doi.org\/10.1089\/dna.2008.0781","journal-title":"DNA Cell Biol"},{"key":"490_CR49","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","volume":"2","author":"CA Shu","year":"2016","unstructured":"Shu CA, Pike MC, Jotwani AR et al (2016) Uterine cancer after Risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2:1434\u20131440. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1820","journal-title":"JAMA Oncol"},{"key":"490_CR50","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1086\/375121","volume":"72","author":"H Meijers-Heijboer","year":"2003","unstructured":"Meijers-Heijboer H, Wasielewski M, Wagner A et al (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308\u20131314. https:\/\/doi.org\/10.1086\/375121","journal-title":"Am J Hum Genet"},{"key":"490_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-009-0634-4","volume":"123","author":"M Wasielewski","year":"2010","unstructured":"Wasielewski M, Riaz M, Vermeulen J et al (2010) Association of rare MSH6 variants with familial breast cancer. Breast Cancer Res Treat 123:315\u2013320. https:\/\/doi.org\/10.1007\/s10549-009-0634-4","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","volume":"14","author":"MJ Hall","year":"2021","unstructured":"Hall MJ, Bernhisel R, Hughes E et al (2021) Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) gene are associated with high and moderate risks for multiple cancers. Cancer Prev Res Phila Pa 14:433\u2013440. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0448","journal-title":"Cancer Prev Res Phila Pa"},{"key":"490_CR53","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jamaoncol.2016.5194","volume":"3","author":"R Pearlman","year":"2017","unstructured":"Pearlman R, Frankel WL, Swanson B et al (2017) Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3:464\u2013471. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5194","journal-title":"JAMA Oncol"},{"key":"490_CR54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/j.1349-7006.2000.tb01028.x","volume":"91","author":"K Kimura","year":"2000","unstructured":"Kimura K, Shinmura K, Yoshimura K et al (2000) Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res Gann 91:875\u2013879. https:\/\/doi.org\/10.1111\/j.1349-7006.2000.tb01028.x","journal-title":"Jpn J Cancer Res Gann"},{"key":"490_CR55","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s12032-021-01495-w","volume":"38","author":"SK McKinley","year":"2021","unstructured":"McKinley SK, Singh P, Yin K et al (2021) Disease spectrum of gastric cancer susceptibility genes. Med Oncol Northwood Lond Engl 38:46. https:\/\/doi.org\/10.1007\/s12032-021-01495-w","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"490_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/gastro\/goab020","volume":"9","author":"Y-J Zhang","year":"2021","unstructured":"Zhang Y-J, Yang Y, Wei Q et al (2021) A multicenter study assessing the prevalence of germline genetic alterations in Chinese gastric-cancer patients. Gastroenterol Rep 9:339\u2013349. https:\/\/doi.org\/10.1093\/gastro\/goab020","journal-title":"Gastroenterol Rep"},{"key":"490_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10689-012-9599-2","volume":"12","author":"U Teodorczyk","year":"2013","unstructured":"Teodorczyk U, Cybulski C, Woko\u0142orczyk D et al (2013) The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer 12:473\u2013478. https:\/\/doi.org\/10.1007\/s10689-012-9599-2","journal-title":"Fam Cancer"},{"key":"490_CR58","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1159\/000505664","volume":"98","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhao Z, Zhang Y et al (2020) Pathogenic germline mutations in Chinese patients with gastric cancer identified by Next-Generation sequencing. Oncology 98:583\u2013588. https:\/\/doi.org\/10.1159\/000505664","journal-title":"Oncology"},{"key":"490_CR59","doi-asserted-by":"publisher","unstructured":"G\u0105sior-Perczak D, Kowalik A, Gruszczy\u0144ski K et al (2021) Incidence of the CHEK2 germline mutation and its impact on clinicopathological features, treatment responses, and disease course in patients with papillary thyroid carcinoma. Cancers. https:\/\/doi.org\/10.3390\/cancers13030470","DOI":"10.3390\/cancers13030470"},{"key":"490_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13053-022-00211-7","volume":"20","author":"K Koen","year":"2022","unstructured":"Koen K, Robin DP, Eline N (2022) CHEK2 mutations and papillary thyroid cancer: correlation or coincidence? Hered Cancer Clin Pract 20:5. https:\/\/doi.org\/10.1186\/s13053-022-00211-7","journal-title":"Hered Cancer Clin Pract"},{"key":"490_CR61","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jdv.16729","volume":"35","author":"AN Bui","year":"2021","unstructured":"Bui AN, LeBoeuf NR, Nambudiri VE (2021) Skin cancer risk in CHEK2 mutation carriers. J Eur Acad Dermatol Venereol JEADV 35:353\u2013359. https:\/\/doi.org\/10.1111\/jdv.16729","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"490_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41431-021-01013-6","volume":"30","author":"A McGuigan","year":"2022","unstructured":"McGuigan A, Whitworth J, Andreou A et al (2022) Multilocus inherited neoplasia allele syndrome (MINAS): an update. Eur J Hum Genet EJHG 30:265\u2013270. https:\/\/doi.org\/10.1038\/s41431-021-01013-6","journal-title":"Eur J Hum Genet EJHG"},{"key":"490_CR63","doi-asserted-by":"publisher","first-page":"e2300190","DOI":"10.1200\/PO.23.00190","volume":"7","author":"S Sorscher","year":"2023","unstructured":"Sorscher S, LoPiccolo J, Heald B et al (2023) Rate of pathogenic germline variants in patients with lung cancer. JCO Precis Oncol 7:e2300190. https:\/\/doi.org\/10.1200\/PO.23.00190","journal-title":"JCO Precis Oncol"},{"key":"490_CR64","doi-asserted-by":"publisher","first-page":"107864","DOI":"10.1016\/j.lungcan.2024.107864","volume":"194","author":"O Arrieta","year":"2024","unstructured":"Arrieta O, Caball\u00e9-P\u00e9rez E, Hern\u00e1ndez-Pedro N et al (2024) Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: the GERMLUNG study. Lung Cancer Amst Neth 194:107864. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107864","journal-title":"Lung Cancer Amst Neth"},{"key":"490_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS et al (2024) Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 22:249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Cancer Netw JNCCN"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T08:17:31Z","timestamp":1765009051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00490-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6406420\/v1","asserted-by":"object"}]},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants in this study were conducted per the ethical standards of the institutional and\/or national research committee, the 1964 Helsinki Declaration, and its subsequent amendments or comparable ethical standards. This study was approved by the Research and Bioethics Committee of the National Institute of Genomic Medicine in Mexico (approval numbers: 13\/2017\/E, 22\/2018\/I, and CEI2017\/17).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed a written informed consent for germline multi-gene panel testing and agreed to the use of their data for research and statistical purposes. All participants received pre- and post-test genetic counseling by a certified clinical geneticist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"73"}}